Serina Therapeutics Authorized to Advance Phase 1b Parkinson's Study
The independent Safety Monitoring Committee recommended Serina Therapeutics advance its SER-252 study to Cohort 2 following blinded positive safety and tolerability data in advanced Parkinson's patients. This milestone supports the sustained exposure profile the company designed.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day